Supplement Label Requirements: What Your Designer Must Get Right in 2026

What must legally appear on a US supplement label?

FDA requires five specific statements, split across two zones of the label, and missing even one is misbranding regardless of how good the design looks otherwise. The principal display panel carries the statement of identity and the net quantity of contents; the information panel carries the Supplement Facts panel, the ingredient list, and the name and place of business of the manufacturer, packer or distributor, per FDA's Dietary Supplement Labeling Guide. No non-required material, not even a UPC barcode, is allowed to sit between those information-panel elements.

The statement of identity has its own type rules. It must use the word "dietary" (or the specific ingredient name, as in "herbal supplement") in bold type sized relative to the boldest print on the front panel, under 21 CFR 101.3. Net quantity of contents has to sit as its own distinct line in the bottom 30% of the front panel, unless that panel is 5 square inches or smaller, under 21 CFR 101.105.

Facility registration is a separate federal duty and easy to conflate with product approval — a mistake that shows up constantly in how brands brief designers. Registering a manufacturing site under 21 CFR 1.225 is a paperwork obligation that belongs squarely to the brand, not a badge the label can lean on, and FDA states plainly that "mere registration of an establishment... does not denote approval," a distinction covered in the duties that actually belong to the brand, not the co-packer.

• Statement of identity — principal display panel, bold type
• Net quantity of contents — bottom 30% of principal display panel
• Supplement Facts panel — information panel
• Ingredient list — information panel
• Name and place of business of manufacturer, packer or distributor — information panel

How does a Supplement Facts panel differ from Nutrition Facts?

A Supplement Facts panel is a distinct, separately regulated panel, not a rebadged Nutrition Facts label. Under 21 CFR 101.36 the panel must be headed "Supplement Facts" in type larger than everything else in the panel, boxed with hairlines, set in uniform type no smaller than 8 point (6 point for column headers and footnotes) — a Nutrition Facts panel follows its own separate format governing conventional foods and doesn't carry these supplement-specific rules.

Two structural quirks set it apart further. Ingredients that have no established RDI or DRV — most botanicals, many amino acids — get declared below a heavy bar rather than mixed in above it. Proprietary blends are allowed to disclose only the blend's total weight, with individual constituents listed in descending order by weight rather than broken out with their own amounts — a loophole that conventional food labels don't have because they don't carry proprietary-blend declarations at all.

Which claims can a label make without triggering FDA drug rules?

Structure/function claims — "supports joint comfort," "helps maintain cholesterol levels already in the normal range" — are allowed without premarket FDA approval, but only with the standard disclaimer attached under 21 CFR 101.93, and only after the firm notifies FDA's Office of Dietary Supplement Programs within 30 days of first marketing the claim. Cross into disease-claim language — "treats," "cures," "prevents [named disease]" — and the product functions as an unapproved drug in FDA's eyes, disclaimer or not.

Most operators treat the disclaimer box as the compliance mechanism, and it isn't. Since DSHEA gives FDA no authority to approve a supplement before it reaches the shelf and no obligation to test it before sale, nothing in the label design process actually screens claim language before the product ships — the disclaimer satisfies a formatting requirement, not a safety review, and a boxed disclaimer sitting next to a disease claim is still a disease claim. That gap between "labeled correctly" and "claimed legally" is the same gap that determines how direct compliant ad copy can get once the same claims move from packaging to a landing page.

Where does the FDA disclaimer have to appear?

The disclaimer sits immediately next to the structure/function claim it covers, not buried in fine print elsewhere on the label. 21 CFR 101.93 requires the full text — "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." — in boldface type no smaller than one-sixteenth inch, boxed, with no unrelated material between the claim and the disclaimer, or connected to the claim by a clear reference symbol.

One disclaimer can cover multiple claims on the same label, provided the wording switches to plural — "These statements have not been evaluated..." — rather than repeating the singular version once per claim. Designers who paste the disclaimer into a footer far from the claim, or split it across a barcode block, create exactly the kind of intervening-material problem FDA's placement rule exists to prevent.

What allergen and ingredient listing rules apply?

US law recognizes nine major food allergens, and a supplement carrying any of them must disclose it plainly rather than relying on the ingredient list's Latin or trade names to do the job. FALCPA requires either the word "Contains" followed by the allergen's common name printed adjacent to the ingredient list, or the allergen named in parentheses inside the list itself — designer's choice, not FDA's.

Gelatin capsules, fish-oil softgels and dairy-derived probiotic strains are the ingredients that most often get missed, because the allergen sits inside a processing aid or carrier rather than the headline active. A designer working from a formulation sheet that lists "gelatin" but omits a fish-source declaration on a marine-sourced capsule, or drops soy lecithin's soy disclosure, is producing a misbranded label even if every other panel element is correct.

• Milk
• Eggs
• Fish
• Crustacean shellfish
• Tree nuts
• Peanuts
• Wheat
• Soybeans
• Sesame (added January 1, 2023 under the FASTER Act)

How much does professional label design and compliance review cost?

Print cost is the easiest number to pin down, and it drops sharply with volume — a printed pressure-sensitive label runs roughly $0.22 per unit at 500 units, $0.15 at 1,000, $0.10 at 5,000 and $0.07 at 10,000-plus, per one packaging cost guide [likely], with carton and shrink-sleeve costs following the same downward curve. On top of that, expect a one-time $500–$2,000 for label design and print-plate setup, a figure that reads as approximate rather than fixed across vendors.

Compliance review — an attorney or regulatory consultant checking claim language, disclaimer placement and allergen statements before print — has no published rate card among the sources checked for this page, so treat any number quoted to you as needing verification rather than a benchmark. Budget it as a line item separate from design, and hold onto the documentation, since the same substantiation file can feed into what a rebill needs to qualify under Compelling Evidence 3.0 if the offer later runs subscription billing.

What label mistakes have actually gotten products pulled or flagged?

The mistakes that actually get offers pulled are almost never typos — they're claim language and placement errors that formatting alone can't fix. A disease claim dressed up in "supports" language, a disclaimer that isn't boxed or sits a full panel away from the claim it covers, a missing "Contains" statement on a fish-oil softgel, or a UPC code wedged between the ingredient list and the manufacturer's address all constitute misbranding under the rules covered above, independent of how the rest of the label looks.

The downstream cost compounds past the reprint. A misbranded label that draws an FDA warning letter or a retailer takedown often shows up next on a payment processor's radar, and once a merchant has been shut down for cause, getting back off the list that flags supplement merchants as high-risk takes months, not a redesign cycle. Treat the label review as a gate before the print run, not a step you revisit after the first chargeback wave.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For educational pages, the supporting references should help readers verify search, crawlability, and public ad research context, especially Google helpful content guidance, Google SEO link best practices, and Meta Ad Library. Daily Intel then adds the direct-response interpretation layer so the page explains what the signal means for actual affiliate research decisions.

For deeper evaluation, continue through Daily Intel research methodology, Is It Too Late for the GLP-1 Wave? A Saturation Timing Read, The GLP-1 Economy: A Market Map for Media Buyers, The Compounded Semaglutide Crackdown, Explained for Affiliates, How Telehealth Funnels Work: Quiz, Doctor, Pharmacy, Payout, and What is a VSL?. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.